×
Puma Biotechnology Long Term Debt 2010-2024 | PBYI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Puma Biotechnology long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
View More
Puma Biotechnology Long Term Debt 2010-2024 | PBYI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Puma Biotechnology long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$178.9B
Regeneron Pharmaceuticals (REGN)
$125.5B
Vertex Pharmaceuticals (VRTX)
$122.4B
Gilead Sciences (GILD)
$104.4B
Bristol Myers Squibb (BMY)
$100.8B
CSL (CSLLY)
$96.8B
GSK (GSK)
$87.9B
Alnylam Pharmaceuticals (ALNY)
$35.1B
Argenex SE (ARGX)
$31.6B
Biogen (BIIB)
$28.8B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$26.9B
Illumina (ILMN)
$20.9B
BeiGene (BGNE)
$19.2B
Genmab (GMAB)
$17.3B
BioMarin Pharmaceutical (BMRN)
$13.5B
Vaxcyte (PCVX)
$13B
Exact Sciences (EXAS)
$12.8B
Incyte (INCY)
$12.6B
Insmed (INSM)
$12.5B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.4B
Bio-Rad Laboratories (BIO.B)
$9.1B
Legend Biotech (LEGN)
$9.1B
Roivant Sciences (ROIV)
$8.9B
Ascendis Pharma (ASND)
$8.7B
Repligen (RGEN)
$8B
Halozyme Therapeutics (HALO)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B